<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108741</url>
  </required_header>
  <id_info>
    <org_study_id>V1 19.09.2019</org_study_id>
    <nct_id>NCT04108741</nct_id>
  </id_info>
  <brief_title>Augmented Reality Treadmill Training in Patients With Parkinson's Disease</brief_title>
  <acronym>Falls in PD</acronym>
  <official_title>Augmented Reality Treadmill Training in Patients With Parkinson's Disease: a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinik Valens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinik Valens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gait disorder is a disabling symptom in Parkinson's disease (PD) affecting all patients&#xD;
      during the course. Three methods of treadmill training (TT) will be compared to assess&#xD;
      additional augmented reality (AR), or additional dual task (DT). AR TT, DT TT, and TT alone&#xD;
      applied over 3 weeks at each day will be compared for their impact on falls, walking,&#xD;
      freezing and attention for 3 months in a double blinded randomized controlled trial during&#xD;
      regular neurorehabilitation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of falls</measure>
    <time_frame>3 months before study to 3 months following the study</time_frame>
    <description>group difference of the difference in falls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes:</measure>
    <time_frame>before and after the training period of 3 weeks</time_frame>
    <description>Freezing of Gait (FOG) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensor based gait analyses</measure>
    <time_frame>before and after the training period of 3 weeks and after 3 months</time_frame>
    <description>for one week</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Fall</condition>
  <arm_group>
    <arm_group_label>treadmill training with augmented reality dual tasking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>treadmill training with random number generation dual tasking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>treadmill training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>C-Mill augmented reality treadmill training</intervention_name>
    <description>PD Patients will be randomized to treadmill training with augmented reality or to treadmill training with random number generation or to treadmill training for 3 weeks at 5 days a week for 30 minutes.</description>
    <arm_group_label>treadmill training</arm_group_label>
    <arm_group_label>treadmill training with augmented reality dual tasking</arm_group_label>
    <arm_group_label>treadmill training with random number generation dual tasking</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
          -  ParkinsonÂ´s disease without dementia and hallucination&#xD;
&#xD;
          -  at least one fall within the past 3 months or postural instability&#xD;
&#xD;
          -  Gait disorder&#xD;
&#xD;
          -  Hoehn and Yahr stages II-IV&#xD;
&#xD;
          -  able to perform the treadmill therapy during a study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to treadmill therapy (e.g. hip fracture)&#xD;
&#xD;
          -  Dementia as defined by an Montreal cognitive assessment (MOCA) &lt; 20&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veit Mylius, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Kliniken Valens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veit Mylius, Prof. Dr.</last_name>
    <phone>0041813031406</phone>
    <email>veit.mylius@kliniken-valens.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology</name>
      <address>
        <city>Valens</city>
        <state>Saint Gallen</state>
        <zip>7317</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veit Mylius, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinik Valens</investigator_affiliation>
    <investigator_full_name>Veit Mylius</investigator_full_name>
    <investigator_title>Priniciple Investigator</investigator_title>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

